JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 25:65-69
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moya, A
Right arrow Articles by Soler-Soler, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moya, A
Right arrow Articles by Soler-Soler, J

Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo

A Moya, G Permanyer-Miralda, J Sagrista-Sauleda, X Carne, T Rius, L Mont, and J Soler-Soler

Servei de Cardiologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

OBJECTIVES. This study assessed the efficacy of oral etilefrine (10 mg three times a day) in preventing a positive response to head-up tilt testing. BACKGROUND. Previous reports have suggested that oral etilefrine can be effective either in preventing a positive response to head-up tilt testing or in reducing syncopal recurrences in patients with vasovagal syncope. Up to now most studies assessing drug therapy in these patients have been uncontrolled. METHODS. This was a randomized double-blind crossover study of etilefrine versus placebo in 30 consecutive patients with syncope and a baseline positive head-up tilt test. After the first test, patients had no treatment for 3 days and were randomized to receive etilefrine or placebo for 4 additional days. They underwent tilt testing under treatment and again after 3 days of washout; they then received the alternative treatment for 4 days, and a third test was performed. RESULTS. Head-up tilt test results were negative in 13 (43%) patients with etilefrine and 15 (50%) with placebo (p = NS). Therefore, the statistical power of the study was only 10%. The rate of positive responses decreased with repeated testing irrespective of the assigned treatment: A positive response was obtained during the second head-up tilt test in 20 patients (10 with placebo, 10 with etilefrine) but in only 12 during the third (7 with etilefrine, 5 with placebo) (p < 0.05). CONCLUSIONS. Oral etilefrine (10 mg three times a day) was not superior to placebo in preventing a positive response to head-up tilt testing. Despite a low statistical power, the high rate of negative response with placebo (50%) suggests that controlled trials are needed to assess the real efficacy of any treatment in patients with vasovagal syncope.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
M. P. Tan and S. W. Parry
Reply.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2372 - 2373.
[Full Text] [PDF]


Home page
EuropaceHome page
S. Petkar and A. Fitzpatrick
Tilt-table testing: transient loss of consciousness discriminator or epiphenomenon?
Europace, June 1, 2008; 10(6): 747 - 750.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
M. Brignole, F. Giada, A. Raviele, and J. J. Blanc
Pacing for syncope: what role? which perspective?
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I37 - I43.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Europace, October 1, 2007; 9(10): 959 - 998.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Eur. Heart J., September 2, 2007; 28(18): 2256 - 2295.
[Full Text] [PDF]


Home page
EuropaceHome page
G. N. Theodorakis, D. Leftheriotis, E. G. Livanis, P. Flevari, G. Karabela, N. Aggelopoulou, and D. Th. Kremastinos
Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study.
Europace, March 1, 2006; 8(3): 193 - 198.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology
Europace, January 1, 2004; 6(6): 467 - 537.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, and J. Soler-Soler
Reproducibility of sequential head-up tilt testing in patients with recent syncope, normal ECG and no structural heart disease
Eur. Heart J., November 1, 2002; 23(21): 1706 - 1713.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Flevari, E. G. Livanis, G. N. Theodorakis, E. Zarvalis, T. Mesiskli, and D. T. h Kremastinos
Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being
J. Am. Coll. Cardiol., August 7, 2002; 40(3): 499 - 504.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Kouakam, G. Vaksmann, E. Pachy, D. Lacroix, C. Rey, and S. Kacet
Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence
Eur. Heart J., September 1, 2001; 22(17): 1618 - 1625.
[Abstract] [PDF]


Home page
Eur Heart JHome page
Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al.
Guidelines on management (diagnosis and treatment) of syncope
Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
A. H. Madrid, J. Ortega, J. G. Rebollo, J. G. Manzano, J. G. Segovia, A. Sanchez, G. Pena, and C. Moro
Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study
J. Am. Coll. Cardiol., February 1, 2001; 37(2): 554 - 559.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Sheldon and S. Rose
Components of clinical trials for vasovagal syncope
Europace, January 1, 2001; 3(3): 233 - 240.
[Abstract] [PDF]


Home page
EuropaceHome page
A. Raviele, F. Giada, R. Sutton, P. Alboni, M. Brignole, A. Del Rosso, E. di Girolamo, R. Luise, and C. Menozzi
The Vasovagal Syncope and Pacing (Synpace) trial: rationale and study design
Europace, January 1, 2001; 3(4): 336 - 341.
[Abstract] [PDF]


Home page
QJMHome page
S.W. Parry and R.A. Kenny
The management of vasovagal syncope
QJM, December 1, 1999; 92(12): 697 - 705.
[Full Text] [PDF]


Home page
CirculationHome page
D. G. Benditt, G. J. Fahy, K. G. Lurie, S. Sakaguchi, W. Fabian, and N. Samniah
Pharmacotherapy of Neurally Mediated Syncope
Circulation, September 14, 1999; 100(11): 1242 - 1248.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Raviele, M. Brignole, R. Sutton, P. Alboni, P. Giani, C. Menozzi, and A. Moya
Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial
Circulation, March 23, 1999; 99(11): 1452 - 1457.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, T. Rius-Gelabert, L. Mont Girbau, and J. Soler-Soler
Clinical usefulness of head-up tilt test in patients with syncope and intraventricular conduction defect
Europace, January 1, 1999; 1(1): 63 - 68.
[Abstract] [PDF]


Home page
EuropaceHome page
D. Flammang, M. Antiel, T. Church, A. Chassing, D. Hamani, E. Donal, and M. Waynberger
Is a pacemaker indicated for vasovagal patients with severe cardioinhibitory reflex as identified by the ATP test?: A preliminary randomized trial
Europace, January 1, 1999; 1(2): 140 - 145.
[Abstract] [PDF]


Home page
HeartHome page
C R Ward, J C Gray, J J Gilroy, and R A Kenny
Midodrine: a role in the management of neurocardiogenic syncope
Heart, January 1, 1998; 79(1): 45 - 49.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.